Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Thrombosis and Thrombolysis
Metadata
Title
The Post-thrombotic Syndrome: The Forgotten Morbidity of Deep Venous Thrombosis
Author
Susan R. Kahn, MD, MSc
Publication date
01-02-2006
Publisher
Kluwer Academic Publishers
Published in
Journal of Thrombosis and Thrombolysis / Issue 1/2006
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-006-5574-9

Other articles of this Issue 1/2006

Journal of Thrombosis and Thrombolysis 1/2006 Go to the issue

OriginalPaper

Perioperative Management of Oral Anticoagulation: When and How to Bridge

OriginalPaper

Low Intensity Warfarin Anticoagulation is Safe and Effective as a Long-Term Venous Thromboembolism Prevention Strategy

OriginalPaper

The Standard is Still the Standard or Why an INR of 2–3 is Still the Optimal Intensity for Secondary Prevention of Venous Thromboembolism

OriginalPaper

New Anticoagulants: Anti IIa vs Anti Xa—Is One Better?

OriginalPaper

The Antiphospholipid Syndrome: What are We Really Measuring? How do We Measure it? And How do We Treat it?

OriginalPaper

Worldwide Management of Oral Anticoagulant Therapy: the ISAM Study

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits